Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has maintained its Buy rating on Kymera Therapeutics and increased the price target from $45 to $52.

November 01, 2024 | 7:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has reaffirmed its Buy rating on Kymera Therapeutics and increased the price target from $45 to $52, indicating confidence in the company's future performance.
The increase in price target from $45 to $52 by Guggenheim suggests a positive outlook on Kymera Therapeutics' future performance. Maintaining a Buy rating indicates continued confidence in the stock, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100